TY - JOUR
T1 - TMS Database Registry Consortium Research Project in Japan (TReC-J) for Future Personalized Psychiatry
AU - Noda, Yoshihiro
AU - Kizaki, Junichiro
AU - Takahashi, Shun
AU - Mimura, Masaru
N1 - Funding Information:
proach required for the future of psychiatry is not “a uniform treatment for a specific diagnosis” but approach required for the future of psychiatry is not “a uniform treatment for a specific diagnosis” “redefinition of diseases based on biotypes related to each diagnosis and development of effective treatments for each biotype”. To realize this goal, it is essential to establish the TMS registry as pro- treatments for each biotype”. To realize this goal, it is essential to establish the TMS registry as proposed in this protocol and commission paper. Currently, a number of collaborative research sites from all over Japan are participat- Ainugth ionr Cthoen TtrMibuSt idoantsa:bCaosnecreepgtuisatlrizya ptioronj,eYc.tN, .a; nmde tahno daolllo-Jgayp, aJ.nK .p; sroofjtewcatries, bJ.Kei.n; ign vinesittiigaatetido nt,oYe.Nn.- aanbdleS.Tth.;er efsiorsutr cbeisg, Yd.Nat.a; warnitailnygs—iso rreiglaintaeldd troaf tTpMreSp athraetrioanp,yY.. NTh.; iws rrietignigs—tryre vpireowjeacntdweidlilt ianlgso, J.dKe.,-velop a feedback loop to provide the results of the analysis to the data providers (each principal investigator and each subject). Such services will also enable the collection of use cases for clinical and healthcare applications and data utilization in the area of psychiatric (AdiMsoErDd)e,r2s0,d sku0c3h07a0s9 e3ahr0l0y01d;e2t1edckti0o3n0 7a0n9d3h i0n0t0e2rv. ention to prevent the onset of mood disorders and to initiate treatment at a milder stage of symptoms. Institutional Review Board Statement: The study was conducted in accordance with the Declaration Furthermore, as a future prospect, after the database registry project in Japan gets on of Helsinki and approved by the Ethics Committee of the Kyoto University Graduate School and track, we would like to expand and develop this registry project to include not only do- Faculty of Medicine (protocol code: R3015 and date of approval: 24 June 2021). mestic but also foreign collaborating research institutes to enable mutual data sharing un-Informedder certain coConsentnditions. Statement: Not applicable for this protocol and commission paper. Data Availability Statement: The dataset constructed and consolidated in this registry project may Author Contributions: Conceptualization, Y.N.; methodology, J.K.; software, J.K.; investigation, Y.N. and S.T.; resources, Y.N.; writing—original draft preparation, Y.N.; writing—review and editing, J.K., S.T., and M.M.; visualization, J.K.; supervision, Y.N. and M.M.; project administration, Y.N.; funding acquisition, Y.N. All authors have read and agreed to the published version of the manuscript. Acknowledgments: Y.N. has received a Grant-in-Aid for Scientific Research (B) (21H02813) from the Funding: This research was funded by the Japan Agency for Medical Research and Development Research and Development (AMED), investigator-initiated clinical study grants from Teijin Pharma
Funding Information:
This research was funded by the Japan Agency for Medical Research and Development (AMED), 20dk0307093h0001; 21dk0307093h0002.
Funding Information:
Data Availability Statement: The dataset constructed and consolidated in this registry project may be made available by the principal investigator if the content and purpose of the analysis proposed by the members of the Japan Society for Clinical TMS Research are appropriate and reasonable after for an investigator-initiated study from Magventure Inc., Inter Reha Co., Ltd., Brainbox Ltd., and Miyuki Giken Co., Ltd. S.T. received speaker’s honoraria from Teijin Pharma Ltd. within the past Acknowledgments: Y.N. has received a Grant-in-Aid for Scientific Research (B) (21H02813) from the Japan Society for the Promotion of Science (JSPS), research grants from Japan Agency for Medical Research and Development (AMED), investigator-initiated clinical study grants from Teijin Pharma Ltd. and Inter Reha Co., Ltd. He has also received research grants from Japan Health Foun-
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/5
Y1 - 2022/5
N2 - The registry project led by the Japanese Society for Clinical Transcranial Magnetic Stimulation (TMS) Research aims to establish a centralized database of epidemiological, clinical, and biological data on TMS therapy for refractory psychiatric disorders, including treatment-resistant depression, as well as to contribute to the elucidation of the therapeutic mechanism of TMS therapy and to the validation of its efficacy by analyzing and evaluating these data in a systematic approach. The objective of this registry project is to collect a wide range of complex data linked to patients with various neuropsychiatric disorders who received TMS therapy throughout Japan, and to make effective use of these data to promote cross-sectional and longitudinal exploratory observational studies. Research utilizing this registry project will be conducted in a multicenter, non-invasive, retrospective, and prospective observational research study design, regardless of the framework of insurance medical care, private practice, or clinical research. Through the establishment of the registry, which aims to make use of data, we will advance the elucidation of treatment mechanisms and identification of predictors of therapeutic response to TMS therapy for refractory psychiatric disorders on a more real-world research basis. Furthermore, as a future vision, we aim to develop novel neuromodulation medical devices, algorithms for predicting treatment efficacy, and digital therapeutics based on the knowledge generated from this TMS registry database.
AB - The registry project led by the Japanese Society for Clinical Transcranial Magnetic Stimulation (TMS) Research aims to establish a centralized database of epidemiological, clinical, and biological data on TMS therapy for refractory psychiatric disorders, including treatment-resistant depression, as well as to contribute to the elucidation of the therapeutic mechanism of TMS therapy and to the validation of its efficacy by analyzing and evaluating these data in a systematic approach. The objective of this registry project is to collect a wide range of complex data linked to patients with various neuropsychiatric disorders who received TMS therapy throughout Japan, and to make effective use of these data to promote cross-sectional and longitudinal exploratory observational studies. Research utilizing this registry project will be conducted in a multicenter, non-invasive, retrospective, and prospective observational research study design, regardless of the framework of insurance medical care, private practice, or clinical research. Through the establishment of the registry, which aims to make use of data, we will advance the elucidation of treatment mechanisms and identification of predictors of therapeutic response to TMS therapy for refractory psychiatric disorders on a more real-world research basis. Furthermore, as a future vision, we aim to develop novel neuromodulation medical devices, algorithms for predicting treatment efficacy, and digital therapeutics based on the knowledge generated from this TMS registry database.
KW - database
KW - registry
KW - stratified psychiatry
KW - the Japan Society for Clinical TMS Research
KW - transcranial magnetic stimulation (TMS)
KW - treatment-resistant depression (TRD)
UR - http://www.scopus.com/inward/record.url?scp=85131163719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131163719&partnerID=8YFLogxK
U2 - 10.3390/jpm12050844
DO - 10.3390/jpm12050844
M3 - Article
AN - SCOPUS:85131163719
SN - 2075-4426
VL - 12
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
IS - 5
M1 - 844
ER -